Enkephalins (met-enkephalin: Tyr-Gly-Gly-Phe-Met; leu-enkephalin: Tyr-Gly-Gly-Phe-Leu) are pentapeptide endogenous opioid Neuropeptides cleaved from proenkephalin by prohormone convertases. They function as rapid-acting, short-lived pain modulators and immune regulators, binding preferentially to delta-opioid receptors (DOR) and with lower affinity to mu-opioid receptors (MOR). Unlike systemically administered opioids, enkephalins provide highly localized analgesia at multiple anatomical sites including spinal Dorsal Horn, Periaqueductal Gray, inflammation sites, and reward circuits.
Think of enkephalins as emergency fire extinguishers mounted throughout a building. They're small, designed for immediate use, and placed strategically where fires (pain signals) are most likely to start: at the doorway where danger enters (spinal cord first relay station), in the command center (brainstem pain control), and right at the scene of the fire (inflamed tissue). When you pull the trigger, they spray for only seconds before the chemical runs out—their half-life is under one minute, like foam that evaporates almost instantly. Unlike calling the fire brigade (systemic morphine), these local extinguishers don't affect the whole building; they cool down just the immediate hot spot. The extinguishers are refillable: Exercise, acute stress, and even local immune cells can reload them. But if you pull the trigger too often (chronic opioid exposure), the valve gets sticky and stops responding—this is Opioid Tolerance. Enkephalins are the body's first-responder analgesia system, designed for spot fires, not for controlling a warehouse blaze.
Enkephalins are synthesized as part of the 267-amino-acid precursor proenkephalin (PENK), which contains four met-enkephalin sequences and one leu-enkephalin sequence. Prohormone convertases 1 and 2 (PC1/2) cleave proenkephalin at paired basic residues in:
Receptor Binding and Signal Transduction:
Met-enkephalin and leu-enkephalin bind:
- DOR (delta-opioid receptor): Kd ~1-5 nM (high affinity, primary target)
- MOR (mu-opioid receptor): Kd ~50-200 nM (10-40× lower affinity, secondary target)
- KOR (kappa-opioid receptor): minimal binding
Upon receptor activation:
- Gi/Go protein activation → inhibition of adenylyl cyclase → ↓cAMP → ↓PKA activity
- Direct Gβγ-mediated effects:
- Close voltage-gated Calcium channels (Cav2.1, Cav2.2) → ↓Ca²⁺ influx → ↓neurotransmitter release
- Open G-protein-coupled inward-rectifying potassium channels (GIRK) → K⁺ efflux → hyperpolarization → ↓neuronal excitability
Spinal Analgesia Mechanism:
At the spinal Dorsal Horn first relay synapse:
- Primary afferent nociceptors (C fibers, A-delta fibres) release Substance P and Glutamate from central terminals
- Enkephalinergic interneurons (concentrated in lamina II) release enkephalins
- Enkephalins bind presynaptic DOR on nociceptor terminals → close Calcium channels → ↓Substance P release → ↓activation of second-order neurons in Spinothalamic tract
- Enkephalins also bind postsynaptic DOR on projection neurons → hyperpolarization via K⁺ channels
Descending Pain Modulation:
PAG → rostroventral medulla (RVM) → spinal cord pathway:
Peripheral Immune-Derived Analgesia:
At sites of inflammation:
- leukocytes (particularly T cells, monocytes) express proenkephalin
- Local inflammatory signals (IL-1β, CRH, Noradrenaline) stimulate enkephalin synthesis and release
- Secreted enkephalins bind DOR on peripheral nociceptor terminals → local analgesia
- This mechanism is pH-dependent: acidic inflammatory environments enhance DOR expression on nociceptors
Enzymatic Degradation:
Enkephalins have half-life <1 minute due to rapid cleavage by:
- Neutral endopeptidase (NEP, neprilysin)
- Aminopeptidase N
- Dipeptidyl peptidase III
- This ensures spatially restricted, phasic signaling
graph TD
A[Proenkephalin PENK] -->|PC1/2 cleavage| B[Met-enkephalin]
A -->|PC1/2 cleavage| C[Leu-enkephalin]
B --> D[DOR Kd ~1-5 nM]
B --> E[MOR Kd ~50-200 nM]
C --> D
C --> E
D --> F[Gi/Go activation]
E --> F
F --> G["↓ Adenylyl cyclase"]
F --> H[Close Cav2.1/2.2]
F --> I["Open GIRK K+ channels"]
G --> J["↓ cAMP → ↓ PKA"]
H --> K["↓ Ca²⁺ influx"]
I --> L["K⁺ efflux"]
K --> M["↓ Substance P release"]
L --> N[Hyperpolarization]
M --> O[Spinal Analgesia]
N --> O
B --> P["Degradation <1 min"]
C --> P
P -->|NEP, aminopeptidases| Q[Inactive fragments]
R[Stress/Exercise] --> S[PAG activation]
S --> T[RVM disinhibition]
T --> U[Spinal enkephalin release]
V[Leukocytes at inflammation] -->|"IL-1β, CRH, NE"| W[Peripheral enkephalin]
W --> X[DOR on nociceptors]
X --> Y[Local analgesia]
Pain Modulation Dysfunction in Chronic Pain:
Enkephalin systems become dysfunctional in Chronic Pain states through multiple mechanisms: downregulation of DOR expression, reduced proenkephalin synthesis in spinal interneurons, and accelerated enzymatic degradation. Patients with Fibromyalgia, chronic low-grade inflammation pain syndromes, and Central Sensitization show impaired descending enkephalinergic inhibition from PAG-RVM circuits. This represents a failure of the endogenous analgesia metamodel—the body's own fire extinguishers are empty or broken.
Exercise-Induced Analgesia:
Exercise is one of the most potent stimulators of enkephalin synthesis and release. Acute physical activity increases proenkephalin mRNA in spinal cord and brainstem within 30-60 minutes; chronic training upregulates DOR density and sensitivity. This mechanism underlies exercise-induced hypoalgesia (reduced pain sensitivity lasting 30-60 minutes post-exercise) and contributes to the analgesic effects of Vigorous Intermittent Lifestyle Physical Activity (VILPA). Enkephalins bridge the musculoskeletal-neuro-immune interface: muscle contraction → myokine release → brainstem activation → enkephalin release → pain suppression.
Stress Analgesia and Survival Advantage:
During Acute Stress Response, enkephalins are co-released with Endorphin and Adrenaline to suppress pain and enable fight-or-flight behavior. This is an evolutionary adaptation: an injured animal must suppress pain long enough to escape predation. The PAG is the key integrator: threat signals from Amygdala activate enkephalinergic neurons, producing stress-induced analgesia. In chronic stress, however, this system becomes desensitized (Opioid Tolerance at DOR), contributing to allostatic load and pain sensitization.
Immune-Derived Local Analgesia:
The discovery of leukocyte-derived enkephalins revolutionized pain neuroscience. Inflammation is not purely pro-nociceptive; immune cells at injury sites produce enkephalins to provide endogenous analgesia. This is particularly relevant in Rheumatoid arthritis, inflammatory bowel disease, and post-surgical pain. Clinical implication: interventions that support immune function (adequate protein intake, Omega-3, resolution of chronic inflammation) may enhance this endogenous analgesic mechanism. This is a Selfish Immune System strategy: the immune system controls its own pain signals to prevent excessive avoidance behavior that would impair healing.
Reward, Motivation, and Depression:
Enkephalins in Nucleus Accumbens and ventral Pallidum modulate reward processing and motivation. They interact with Dopamine systems to encode "liking" (hedonic impact) versus "wanting" (incentive salience). Reduced enkephalin signaling in these circuits is implicated in anhedonia, a core feature of Depression and Chronic Fatigue Syndrome. The overlap between chronic pain and depression may reflect shared enkephalin dysfunction across both pain-modulating and reward-processing circuits.
Clinical Thresholds and Biomarkers:
- Pain threshold testing: Enkephalin-mediated analgesia can be assessed via Conditioned Pain Modulation (CPM) testing—impaired CPM (<10% pain reduction) suggests descending inhibitory dysfunction
- Exercise response: Failure to achieve post-exercise hypoalgesia may indicate enkephalin system impairment
- Opioid responsiveness: Patients with reduced enkephalin tone often show poor response to exogenous opioids due to receptor downregulation
Therapeutic Implications:
Rather than administering exogenous opioids (which cause tolerance and dependence), cPNI interventions aim to restore endogenous enkephalin function:
- Two forms: met-enkephalin (Tyr-Gly-Gly-Phe-Met) and leu-enkephalin (Tyr-Gly-Gly-Phe-Leu), differing only in C-terminal amino acid
- Half-life <1 minute in synaptic cleft due to rapid enzymatic degradation by neprilysin and aminopeptidases
- DOR binding affinity Kd ~1-5 nM (high affinity); MOR binding affinity Kd ~50-200 nM (10-40× lower)
- Highest CNS concentrations in spinal Dorsal Horn lamina II, Periaqueductal Gray, Nucleus Accumbens, and Striatum
- Exercise increases proenkephalin mRNA by 50-200% in spinal cord and brainstem within 30-60 minutes of acute activity
- Leukocyte-derived enkephalins provide local analgesia at inflammation sites; production stimulated by IL-1β, CRH, and Noradrenaline
- Stress-induced analgesia mediated by PAG enkephalin release, co-activated with Endorphin systems during Acute Stress Response
- Chronic opioid exposure downregulates DOR expression and causes cross-tolerance to endogenous enkephalins
- pH-sensitive mechanism: acidic environments at inflammation sites enhance DOR expression on nociceptors, amplifying enkephalin analgesia
- Co-localization with GABA: many enkephalinergic interneurons in spinal Dorsal Horn are GABAergic, providing dual inhibitory control
- Endorphin — co-released endogenous opioid during stress; enkephalins act faster (seconds) while endorphins have longer duration (minutes)
- DOR — delta-opioid receptor is primary high-affinity target for enkephalins; mediates spinal and supraspinal analgesia
- MOR — mu-opioid receptor binds enkephalins with 10-40× lower affinity; primary target for Endorphin and exogenous morphine
- KOR — kappa-opioid receptor has minimal enkephalin binding; mediates stress-induced dysphoria via dynorphin
- Substance P — enkephalins presynaptically inhibit Substance P release from nociceptor terminals in spinal Dorsal Horn
- Dorsal Horn — enkephalinergic interneurons in lamina II (substantia gelatinosa) provide first relay modulation of pain signals
- Periaqueductal Gray — high enkephalin content; integrates stress and threat signals to activate descending pain inhibition
- RVM — rostroventral medulla receives PAG input and projects to spinal cord to activate enkephalinergic interneurons
- Acute Stress Response — enkephalins released during fight-or-flight to suppress pain and enable survival behavior
- Immune System — leukocytes synthesize and release enkephalins at inflammation sites for local analgesia
- Inflammation — pro-inflammatory cytokines (IL-1β) paradoxically stimulate immune cell enkephalin production as counter-regulatory mechanism
- Chronic Pain — enkephalin system dysfunction (reduced synthesis, DOR downregulation) contributes to loss of endogenous inhibition
- Exercise — acute and chronic physical activity upregulates proenkephalin expression and DOR sensitivity; mediates exercise-induced hypoalgesia
- Pallidum — enkephalins in ventral pallidum modulate hedonic "liking" component of reward
- Nucleus Accumbens — enkephalinergic medium spiny neurons modulate Dopamine Release and incentive salience
- GABA — enkephalins often co-localized with GABAergic neurons in spinal cord and striatum for combined inhibitory effects
- Dopamine — enkephalins modulate dopaminergic signaling in reward circuits; reduced enkephalin tone linked to anhedonia
- Opioid Tolerance — chronic exogenous opioid use desensitizes DOR and MOR, suppressing endogenous enkephalin efficacy
- Central Sensitization — reduced enkephalinergic inhibition allows unopposed Glutamate and Substance P transmission, facilitating pain amplification
- Depression — enkephalin dysfunction in Nucleus Accumbens and ventral striatum contributes to loss of pleasure response and motivation
- Fibromyalgia — impaired descending enkephalinergic inhibition from PAG-RVM pathway; reduced Conditioned Pain Modulation
- Stress — chronic stress desensitizes enkephalin receptors via sustained activation, contributing to allostatic load
- Myokines — muscle-derived signals during Exercise activate brainstem enkephalin circuits to produce analgesia
- A-delta fibres — fast pain fibers targeted by enkephalin-mediated inhibition at spinal first relay synapse
- C tactile fibres — slow-conducting fibers; enkephalins modulate affective touch processing in Insula
- Pain neuroscience education — can activate placebo-mediated PAG enkephalin release to reduce pain perception
- Noradrenaline — co-released with enkephalins in descending inhibitory pathways; stimulates leukocyte enkephalin production at inflammation sites
- Calcium — enkephalins close voltage-gated calcium channels (Cav2.1, Cav2.2) to reduce neurotransmitter release
- Module 1: Stress pathway, reward circuitry, co-release with Endorphin
- Module 5: Pain modulation, spinal mechanisms, descending inhibition